Takeda Pharmaceutical has recently witnessed a variety of market changes which have led to varying feedback from analysts and investment firms. Despite a downgrade by
Wall Street Zen , others like
Morgan Stanley and
Zacks Research provided an 'overweight' and a 'hold' rating respectively, meaning appraisal remains mixed. The Japanese pharma giant also showed a strong one-year return and positive fair-value signals, although they had to trim their full-year guidance. Key investors such as
Capital Research Global Investors and
XY Capital Ltd have shown confidence by purchasing significant stocks of Takeda. On the downside, firms like
Fisher Asset Management LLC and
First Trust Advisors LP have reduced their stakes. Despite this, the company's relative strength rating has risen to 83, likely from their FDA Priority Review for
Rusfertide and renewed Actos claims. Looking forward, a leadership transition is impending for Takeda, causing a potential impact on its future outlook. Furthermore, Takeda is facing pipeline pressure which could stagger their steady core growth. However, their grand bet on cancer drugs from China and extensive pipeline kaizen project, featuring six drugs worth $20 billion annually, offers some solace and potential for future gains.
Takeda Pharmaceutical Stocks News Analytics from Tue, 08 May 2018 07:00:00 GMT to Sat, 21 Mar 2026 07:01:54 GMT -
Rating 5
- Innovation 7
- Information 8
- Rumor -3
